Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezvilutamide + RP + MDT in Oligometastatic Prostate Cancer
NCT07490210Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- May 2026
- Primary completion
- May 2032
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rezvilutamide in prostate cancer (PCa), sponsored by Fudan University. Planned start May 2026; status: not yet recruiting.
02
Drugs
rezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07490210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07490210.